Transcript Massive Pulmonary Embolism Approach For Management
Pulmonary Thromboembolic Disease
Risk Stratification & Approach For Management Majdy M Idrees Division of Pulmonary Medicine Riyadh Armed Forces Hospital 10 th Advanced Medicine Symposium November 2006 RMH, Riyadh
An Expert: A man who has stopped thinking: He Knows!!
Pulmonary Embolism Risk Stratification & Approach of Management “Venous thrombosis is always a severe disease and is often fatal, because fragments of the thrombi may detach and occlude branches of the pulmonary artery... the occlusion of the main branches of the pulmonary artery causes a striking rise of the blood pressure in these vessels. This rise, which the right heart might fight in order to ensure circulation, may sometimes lead to cardiac arrest.” Picot 1884 Lecons de Clinique Médicale
Pulmonary Embolism Risk Stratification & Approach of Management Definition It is a clinical syndrome of high mortality characterized by acute pulmonary arterial occlusion with resultant sudden elevation in pulmonary artery pressure and right ventricular failure
Pulmonary Embolism
Risk Stratification
Simple
Pulmonary Embolism
Risk Stratification
Complicated
Submassive Massive
Complicated Pulmonary Embolism
Massive Pulmonary Embolism Visual Scoring
1. Perfusion defect >50% 2. Filling defect / obstruction in 2 lobar arteries 3. Obstruction of main (R/L) PA
Functional Scoring
1. Severe refractory hypoxic 2. Hemodynamic instability 3. Acute RV failure 4. Tissue hypoperfusion (low urine output)
Resp rate/min Heart rate/min (A-a)O 2 kPa D-dimer ug/L 4000ug/L < 4000ug/L US proximal DVT Predicting PE Perfusion Defects < 30% 30% - 50% >50% 17 95 3.6
2731 33% 67% (+) 33% (-) 67% 22 99 4.4
6090 67% 33% (+) 76% (-) 24% 28 100 6.3
7950 94% 6% (+) 66% (-) 34% Galle Thromb Haemost 2001; 86:1156-60
PE Severity: Echo Assessment % Obstruction Echo Cor Pulmonale (+) (22) 56% Echo Cor Pulmonale (-) (14) Pulmonary Artery Pressures 28% 36 mmHg (6) 30% - 49% 44 mmHg (20) > 75% Mastora Eur Radiol 2003; 13:29-35
CT Severity Assessment Vascular obstruction index Minimum LV diameter RV/LV Ratio Severe PE (Lysis/Embolectomy) 54% 33 mm 1.63
Non-severe PE (Heparin tx) 24% 40 mm 1.09
Central PA diameter 32 mm 28 mm Collomb Eur Radiol 2003; 13:1508-14
Pathophysiology Obstruction Decreased RV CPP Ischemia VO 2 Wall stress COP / MAP RV Pressure Load RV Decompensation Increase RV Volume • Septal Shift • Pericardial Restriction Decrease LV Distensiblity Decreased LV Preload Neuro-hormonal Decrease RV Output
Vascular Obstruction and Acute Pulmonary Hypertension
70 50 30 10 10 20 30 40
Pulmonary Arterial Mean Pressure (mmHg)
McIntyre Am J Card 1971; 28:288-294
TPVR (mmhg.1.min.m) 30 Vascular Resistance vs Obstruction 20 10 0 10
° °
• •
° °
• • • • •
°
• •
° °
• • • • • • • • •
°
• • • • • 20 Miller index 30 Petitpretz Circ 1984; 70:861-866.
Intervention Diagnostic – Therapeutic Approach
100 Outcome in Pulmonary Embolism Risk Stratification Sudden Death 70 Infliction Point 30 10 0 Hemodynamically Stable & RV Normal Severity Embolism size Cardiac Arrest Shock Cardiopulmonary Status
100 Outcome in Pulmonary Embolism Risk Stratification Sudden Death 70 Cardiac Arrest Shock 30 10 0 Hemodynamically Stable & RV Normal Severity Embolism size Cardiopulmonary Status
Sudden Death in Massive PE • Mortality is almost 100% • No intervention measure has proven effective
Cardiac Arrest
100 Outcome in Pulmonary Embolism Risk Stratification Sudden Death 70 Cardiac Arrest Shock 30 10 0 Hemodynamically Stable & RV Normal Severity Embolism size Cardiopulmonary Status
Echo and Cardiac Arrest • 48 patients in/out hospital cardiac arrest • Diagnosis obtained via TEE 87% • Myocardial infarction 21 • Cardiac tamponade 6 • Pulmonary embolism 6 • Aortic dissection/rupture 5 • Papillary muscle rupture 1 • Absence of cardiac structural abnormalities 7 • Other diagnosis 2 • Sensitivity 93% specificity 50%, positive predictive value • 31% major therapeutic decisions based upon TEE
JACC 30:780-783, 1997
Thrombolysis in CPR • Majority of PE deaths within 1st hour of symptoms • Bolus thrombolysis in arrest- “Reported” • Initiated after failure of conventional CPR • Stabilization 77% Stabilized 67% Survived • Minimal bleeding complications • Microcirculatory Reperfusion Bottiger Fibrinolysis and Proteolysis, 1997
Shock
100 Outcome in Pulmonary Embolism Risk Stratification Sudden Death 70 Cardiac Arrest Shock 30 10 0 Hemodynamically Stable & RV Normal Severity Embolism size Cardiopulmonary Status
The Aphorisms of Hippocrates “In acute diseases,,, coldness of the extremities,, is a very bad sign.”
Study UPET 1970 Alpert 1976 Miller 1977
Pulmonary Embolism Shock vs. Non-Shock Mortality
Treatment Heparin Thrombolysis Heparin Venous Ligation Shock Mortality 36% 25% Non-Shock Mortality 6% 5% Heparin Thrombolysis Embolectomy 22% 11% Verstraete 1988 Thrombolysis 14% 4% Tilsner 1991 Thrombolysis 40% 2%
Major Pulmonary Embolism Diagnostic & Therapeutic Approach Start Heparin Shock ECHO TEE/TTE Certain Diagnoses • Emboli in PA • AMI / Aortic Dissection / Tamponade No RV Pressure Overload?
Alternative DX • Resuscitate & Stabilize Yes Lytic Rx Establish Diagnosis Embolectomy No Yes
+
• Spiral CT • V/Q • Angio
-
Peruse other dx Lysis Candidate
Measures to Improve Hemodynamics
Flow (Cardiac Output)
Heparin Therapy
Exclusion Criteria PIOPED “Patients with shock or major disability due to Pulmonary Embolism were excluded because random assignment to a placebo group was considered unethical.”
PIOPED Investigators CHEST 1990; 97:528-33
Management Massive PE With Shock Heparin Therapy • The efficacy of heparin is attributed to an impairment of clot propagation and the prevention of recurrent PE • Recurrent PE is reported to be the most common cause of death in hemodynamically stable patients Prog Cardiovasc Dis 17 ,257-270 • An inability to establish an early therapeutic level for aPTT is associated with a higher rate of recurrence and impairs the efficacy of anticoagulation therapy with warfarin • It is recommended that heparin therapy be given for 7 to 10 days and that the initiation of warfarin therapy be delayed until the aPTT is at a therapeutic level for 3 days.
Thrombolytic Therapy
Thrombolists Perspective – “Works Great” • Hastens thromboembolic resolution • Removes pulmonary thromboemboli more completely • Hastens dissolution of thrombi in legs • May decrease mortality from pulmonary embolism • May diminish the incidence of chronic thromboembolic pulmonary hypertension Sasahara J Cardiovascular Medicine 1980
Traditionalists Perspective – “Unfulfilling” • Does fibrinolytic therapy
decrease mortality
in acute PE?
• What is the
impact
of fibrinolytic therapy on short and long term recovery from acute PE?
• Does fibrinolytic therapy decrease the rate of
recurrent
PE?
• How do the
complications and Cost
of fibrinolytic therapy compare with those of heparin?
• “Available data does not support the FDA conclusion that fibrinolytic agents are indicated for massive PE… there is insufficient data to determine whether the second approved indication for fibrinolytic therapy – PE accompanied by failure to maintain BP without supportive measures – is appropriate.” Dalen J Cardiovascular Medicine 1980
Thrombolytic Therapy Putative Benefits
PROVEN Accelerated Clot Lysis • Angiograms • Perfusion scans • Pul capillary blood volume Hemodynamic Improvement • Pulmonary pressures • Echocardiogram SPECULATIVE Recurrent Embolism Chronic Pul HTN Quality of Life Symptoms Mortality
Study/Yr UPET ‘73 Tibbutt ‘74 Ly ‘78 PIOPED ‘90 Levine ‘90 Early Resolution Rate Lytic vs Heparin Agent UK SK SK rt-PA rt-PA PAIMS 2 ‘92 Goldhaber ‘93 rt-PA rt-PA Time Post 24 72 72 24 24
2
24 Resolution Lytic Heparin 24.1%* -13.3* -11.3* 10% 8.3% -2.8
-3.4
0% 34.4% -3.5* 14.6%* 12.0% -0.1
1.5% Metric % Scan defect Δ Angio severity Δ Angio severity % Δ mismatch scan defect % showing 50% improvement scan Δ Angio severity % scan
Angiographic Severity UPET UPET JAMA 1970; 214:2163-2172 Complete (91-100%) 4 Severe 3 Marked (61-90%) 3
N = 57 N = 57
Moderate 2 Moderate (31-60%) 2 Minimal 1 Slight Improvement 1 ( 30%) Normal 0 Heparin Urokinase Baseline No change 0 Heparin Urokinase 24 Hours
Rate and Extent Clinical-Hemodynamic Resolution Reported in UPET Heparin Urokinase mRAP mmHg RV Systolic mmHg RVEDP mmHg mPAP mmHg PaO 2 (A-V) O 2 CI L/min•m 2 TPR Baseline 5.86
44.4
8.93
26 62.7
4.92
3.06
5.85
24 hours Δ Baseline 0.33
-3.2
-0.01
-1.18
-0.12
0.08
-0.13
6.58
44.5
9.09
26.3
61.6
4.90
3.15
0.00
5.84
UPET JAMA 1970; 214:2163-2172
24 hours Δ -1.61* -10.1* -2.22* -5.59* 8.33* -0.23
0.07
-0.33*
Total Pulmonary Resistance Evolution 0 Heparin -20 Streptokinase -40 rt-PA -60 0 2 4 6 Time (h) 8 10 12
Meneveau European Heart Journal 1997; 18:1141-1148
Right Ventricular Ejection Fraction Evolution 80 70 60 50 40 30 rt-PA Streptokinase 20 10 Heparin 0 2 4 6 Time (h) 8 10 12
Meneveau European Heart Journal 1997; 18:1141-1148
Recurrent PE With Thrombolytic Therapy Study UPET 1973 Agent Urokinase Heparin 9.0% (7) Lytic 6.1% (5) Levine 1990 PAIMS 2 Goldhaber 1993 Konstantinides 2003 Totals rt-PA rt-PA rt-PA rt-PA rt-PA 0% 0% 3.6% (2) 2.9% (4) 2.3% (5) 0% 5% (1) 0% 3.4% (4) 2.6% (6) Dalen Venous Thromboembolism Lung Biology in Health and Disease 2003
Thrombolytic Therapy Hemorrhagic Complications • Major hemorrhage 8-12% • Similar amongst agents • Fatal hemorrhage 1-2% • Intra-cranial hemorrhage 1.2-2.1% • Fatal in 50%
Arcasoy Chest 1999; 115:1695-1707
Management Massive PE With Shock Surgical Embolectomy • Allows rapid and complete removal of the clot • Survival rate in retrospective review 40-60% Ann Thorac Surg 1991 Cardiac arrest is the most preoperative prognostic factor • Indicated when • Thrombolysis is contraindicated or failed • “Unyeilding” hypotension despite max therapy for > 1 h • Ongoing/intermittent cardiac arrest
Infliction Point
Emboli in Transit RV Dysfunction Submassive Pulmonary Embolism
100 Outcome in Pulmonary Embolism Risk Stratification Sudden Death 70 Infliction Point • RV Dysfunction • Troponin T • NDH 30 10 0 Hemodynamically Stable & RV Normal Severity Embolism size Cardiac Arrest Shock Cardiopulmonary Status
Isolated RV Dysfunction • RV dysfunction has long been recognized as a marker for poor outcome in patients with PE, especially in those with hemodynamic instability • RV dysfunction in hemodynamically stable patients has been identified as a predictor of worse outcome and appears to be related to the presence of recurrent PEs. • 10% of hemodynamically stable patients with RV dysfunction will deteriorate into shock with a 50% mortality rate attributed to those with recurrent PEs
Factor • Systolic arterial hypotension • Congestive heart failure • Cancer • Tachypnea • RV hypokinesis on echo • COPD •Age > 70 Hazard Ratio 2.9
2.4
2.3
2.0
2.0
1.8
1.6
Goldhaber Lancet 1997; 353: 1386-1389
Outcomes Hemodynamically Stable Confirmed PE with RV Dysfunction Tx Heparin Study Goldhaber Grifoni Hamel Giannitsis Viellard-Baron Pruszczyk Pruszczyk Kucher Year 1993 2000 2001 2000 2002 2003 2003 2003 n 23 61 64 26 32 64 51 19 340 PE Deaths 2 3 0 2 1 8 10 2 28 % Mortality 8.7% 5% 0% 7.7% 3% 12.5% 19.6% 10.5% 8.2%
Alteplase vs Heparin Acute PE Assessing RV Function and Perfusion in Hemodynamically Stable Patients Improvement RV wall motion 24 hrs Rt-PA 39% Heparin 17% PVED Area 24 hours 27.5 24 25 25.3
Pulmonary perfusion Recurrent PE Mortality 14.6% 0% 0% 1.5% 9% 2 fatal 3 non fatal All RV Dysfxn 3.6% Goldhaber Lancet 1993; 341:507-11
Major Pulmonary Embolism Thrombolytic Therapy - MAPPET RV Dysfxn + BP-No pressors (719) Mortality Recurrent PE Major bleed Lysis (24%) 4.7% 7.7% 21.9% Heparin (76%) 11.1% 18.7% 7.8% • Clinical factors death: syncope, BP, CHF, COPD • Primary lysis independent predictor of survival • Caution!! Heparin group old, CHF, COPD
Konstantinides Circ 1997; 96:882-888
Non-shock Mortality Thrombolytic Therapy Patients Mortality Study UPET ’73 Urokinase Marini ’88 Urokinase PIOPED ’90 rt-PA Levine ’90 rt-PA PAIMS 2 ’92 rt-PA Goldhaber ’93 rt-PA Konstantinides ’02 rt-PA Total Lytic 73 20 9 33 20 46 118 319 Heparin 73 10 4 25 16 55 138 Lytic % (N) Heparin % (N) 2.7% (2) 0% 11.1% (1) 3.0% (1) 10% (2) 0% 3.4% (4) 8.2% (6) 0% 0% 0% 6.3% (1) 3.6% (2) 2.2% (3) 321 3.1% (10) 3.7% (12)
Submassive Complicated Pulmonary Embolism The role of Thrombolysis Early Lytic Treatment of Submassive Pulmonary Embolism: Clot Dissolving Therapy With Alteplase Plus Heparin Vs Heparin Alone Chest 2003
Submassive Complicated Pulmonary Embolism The role of Thrombolysis • Randomized, DB, multicenter trial • 256 pt • PE confirmed by HP V/Q scan, spiral CT or angiogram • Normal BP • RV dysfunction (Echo, ECG or SG catheter)
Submassive Complicated Pulmonary Embolism The role of Thrombolysis Primary endpoint: • In-hospital mortality • Worsening circulation • Need for additional therapy (surgical embolectomy or adding vasoactive drugs for shock) Secondary endpoint: • 30-days mortality • Recurrent PE
Submassive Complicated Pulmonary Embolism The role of Thrombolysis Results: • The composite primary end point occurred in 11% in alteplase group Vs 24.6% in Heparin group (p=0.0058) • In hospital mortality was the same in both group (2.4% Vs 2.2%), (p=NS) (intention to treat) • Major bleeding was NS (1% Vs 3%), (p=NS) • No significant differences in secondary endpoint
Submassive Complicated Pulmonary Embolism The role of Thrombolysis Conclusion: Administrating the clot-dissolving drug, alteplase, early in the course of massive pulmonary embolism prevents worsening of the disease, and is not associated by increase risk of side effect.
BNP and Troponin Complementary Biomarkers for Risk Stratification Future Directions?
Hemodynamically Stable PE BNP And Stretch RV Dysfxn BNP < 50 detects low risk Troponin Ischemia RV damage TnT > 0.01 detects high risk
Troponin T in Acute PE 56 PE Patients Troponin (+) 32% (18) Troponin (-) 68% (38) RV Dilated 100% (18) Normal 0% (0) Dilated 34% (13) RV Normal 66% (25) Shock (17) Troponin (+) 76% (12) Troponin (-) 24% (5) Giannitsis Cir 2000; 102:211-217
Troponin and PE Clinical Outcome Outcome Hospital death (44% vs 3%) Odds Ratio 29.6
Need for resuscitation Inotropic support Mechanical ventilation Independent predictor 30 day mortality 14.2
5.4
11.5
15.2
Giannitsis Cir 2000; 102:211-217
cTnI, ng/dl < 0.07
0.07 – 1.5
> 1.5
cTnT, ng/dl < 0.04
0.04 – 0.1
> 0.1
Troponin and PE Outcome Mortality (OR) Complicated Course (OR) RV Dysfunction --- 7.15
16.91* --- 2.32
6.50* --- 3.16
15.47* 9.6% 43% 50% --- 4.43* 8.71* 18% 20% 48%
Konstantinides Circ 2002; 106:1263-68
Brain Natriuretic Peptide BNP< 90 pg/ml BNP< 50 pg/ml Sensitivity 85% 95% Specificity 75% 60% Negative 93% 97% Positive 57% 48% • BNP > 90 ng/ml independent predictor adverse (OR 8.0) • “Congestive failure” cut off BNP < 90 ng/dl does NOT guarantee a benign course • BNP < 50 ng/ml predictive value highly sensitive, excellent negative Kucher Circ 2003; 107:1576-78
N-terminal proBNP and Echo Non-massive Submassive Massive BP mmHg RV:LV Deaths SAE BNP pg/mL 132 0.63
0% 0% 363 (56%) 126 0.90
20% • All deaths/SAE in NT-proBNP group • Normal NT-proBNP 100% negative predictive value 83 1.21
44% 31% 78% 4650 (90%) 9865 (100%) • NT-proBNP > 600 96% sensitive 35% specific SAE 100% sensitive 33% specific death Pruszczyk Eur Respir J 2003; 22:649-53
Submassive Pulmonary Embolism Diagnostic-Therapeutic Approach Non Shock Start Heparin Establish Diagnosis Heparin Heparin Vs Lysis Pursue Alternative Diagnosis RV Normal • Spiral CT Scan • V/Q Scan • Angiogram RV Dysfxn Echo + BNP / Troponin Elevated High Risk Floor or Outpatient Normal Low Risk Heparin
Summary
Summary
• Massive pulmonary embolism is rapidly fatal disease • Diagnostic-Therapeutic approach based on risk stratification is probably the most appropriate approach of the management • Normal RV & Normal hemodynamics • RV Dysfunction & Normal hemodynamics • With or without Troponin T level / BNP • Shock • Cardiac arrest • Sudden arrest
Summary
Treatment approach should be directed towards:
• Maintaining oxygenation • Maintaining MAP • Improving Pulmonary hemodynamics (decreasing PAP by simultaneous RV COP and PVR)
Summary
Thrombolytic therapy in massive PE: • Accelerated Clot Lysis • Hemodynamic Improvement • May Improve Recurrent Embolism Chronic Pul HTN Quality of Life Symptoms Mortality Thrombolytic therapy in sub-massive PE: • Controversial issue • Administrating early in the course of sub-massive pulmonary embolism prevents worsening of the disease